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Microbial diversity has been pointed out as a major factor in the development and
progression of colorectal cancer (CRC). We sought to explore the richness and
abundance of the microbial community of a series of colorectal tumor samples treated at
Barretos Cancer Hospital, Brazil, through 16S rRNA sequencing. The presence and the
impact of Fusobacterium nucleatum (Fn) DNA in CRC prognosis was further evaluated
by qPCR in a series of 152 CRC cases. An enrichment for potentially oncogenic bacteria
in CRC was observed, with Fusobacterium being the most abundant genus in the tumor
tissue. In the validation dataset, Fnwas detected in 35/152 (23.0%) of fresh-frozen tumor
samples and in 6/57 (10.5%) of paired normal adjacent tissue, with higher levels in the
tumor (p= 0.0033). FnDNA in the tumor tissue was significantly associated with proximal
tumors (p = 0.001), higher depth of invasion (p = 0.014), higher clinical stages (p =
0.033), poor differentiation (p = 0.011), MSI-positive status (p < 0.0001), BRAF mutated
tumors (p < 0.0001), and the loss of expression of mismatch-repair proteins MLH1 (p <
0.0001), MSH2 (p = 0.003), and PMS2 (p < 0.0001). Moreover, the presence of Fn DNA
in CRC tissue was also associated with a worse patient cancer-specific survival (69.9
vs. 82.2% in 5 years; p = 0.028) and overall survival (63.5 vs. 76.5%; p = 0.037). Here
we report, for the first time, the association of F. nucleatum presence with important
clinical and molecular features in a Brazilian cohort of CRC patients. Tumor detection
and classification based on the gut microbiome might provide a promising approach to
improve the prediction of patient outcome.
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INTRODUCTION
Colorectal cancers (CRCs) are the third most incident tumors
worldwide and the second in mortality rates, with almost
2 million new cases and over 881,000 deaths estimated to occur
in 2018 (1). The increased incidence of CRC in the last decades
can be explained by population aging, poor dietary habits, and
lifestyle factors such as smoking, low physical activity, and obesity
(2, 3). Around 55% of the cases occur in more-developed regions
of the world, with more than half of the deaths occurring in less-
developed regions, reflecting a worse prognosis in these areas
(4). The improvements in survival in developed countries have
been achieved through the adoption of best practices in cancer
treatment and management (3).
In Brazil, CRC is the second most frequent type of cancer in
women and the third most frequent in men (5). A recent study
observed an increase in rate of mortality from CRC in Brazil, for
both men and women when comparing data from 1996 to 2012
(6). These tumors accounted for 5.1% of all death by cancer in
men in 1996 and for 6.9% in 2012; for women, the rates increased
from 6.9% in 1996 to 8.2% in 2012 (6). Therefore, although the
incidence of these tumors in Brazil remains lower than that of
developed, high-income countries, mortality rates are similar,
reflecting the disparity in the mortality–incidence ratio occurring
in Brazil (7, 8).
Diagnosis, prognosis, and therapy choice depend on tumor
classification and staging, which are based on morphology and
histology (9, 10) However, despite an increasing understanding of
the pathophysiology of CRC in the past decades, the introduction
of additional methods that could be accurately used for screening,
risk prediction, prognosis, choice of treatment, and monitoring
in a clinical setting has been challenging.
The majority of CRC cases have a sporadic nature (11).
Genetic, epigenetic, and environmental factors play an important
role in the etiology of CRC through oncogene activation and
tumor suppressor genes silencing, therefore contributing to
the acquisition of hallmark cancer traits in colon epithelial
cells (12). Several studies have been exploring the influence of
microbial diversity in the initiation and progression of these
tumors (13, 14). Several findings point to changes in the
composition and activity of the gut microbiome, creating a
microenvironment that promotes inflammation, proliferation,
and neoplastic progression as a result of an interplay between
these events, host genetics, and other environmental factors
(15, 16). Some bacteria have been reported to be enriched or
diminished in CRC (17). Fusobacterium nucleatum (Fn) strains
are the most consistently reported to promote carcinogenesis
when successful in invading host cells (18–20). However, the
extent of CRC cases that can be attributed to these agents, how
their abundance can affect the gut microbiome, and how they
can be used in a clinical setting in cancer screening, treatment,
or management remains unclear.
Tumor detection and classification based on the gut
microbiome might provide a promising approach to improve
early diagnosis and the prediction of patient outcome. Therefore,
this study unraveled the richness and abundance of the microbial
community of colorectal tumor samples in comparison to healthy
mucosa through 16S rRNA gene sequencing in a small cohort
of patients treated at Barretos Cancer Hospital, and correlated
different microbial phylotypes with clinicopathologic features
and molecular characteristics (such as tumor location, BRAF
mutation, and MSI status). Furthermore, following the observed
enrichment of members of the Fusobacterium genus in CRC
cases, we sought to evaluate the presence of Fn in tumor samples
and adjacent normal mucosa. Besides confirming higher rates
of this bacteria in tumor samples, we also observed significant
associations with important patient clinical features, suggesting
the oncogenic role of this bacteria in CRC carcinogenesis.
MATERIALS AND METHODS
Patient Population and Tissue Samples
This study analyzed samples from 152 patients with CRC
treated surgically at the Department of Colorectal Surgery of
Barretos Cancer Hospital, Barretos, Brazil between 2008 and
2015. Patients were followed for a median of 59.68 months
(ranging from 2.37 to 104.97 months). All samples used were
collected from the surgical resection material. Clinical and
pathological characteristics of patients, such as age, gender,
location of primary tumor, staging, and histological grade,
as well as molecular data on the expression of mismatch
repair proteins (MLH1, MSH6, MSH2, and PMS2), status
of molecular microsatellite instability (MSI) (21), and BRAF
mutation (unpublished data) were available from previous
studies from our group.
Fresh-frozen tumor tissue was available for 152 cases and
paired formalin-fixed paraffin-embedded (FFPE) for 139, while
normal adjacent fresh-frozen tissue was available for a subset of
57 cases. Tumor tissue and normal adjacent mucosa were snap-
frozen immediately following excision of the specimen at surgery
and stored at −80◦C at the Barretos Cancer Hospital Biobank
until processing. Slides from all tissue specimens were carefully
micro-dissected and subjected to histological examination to
confirm the diagnostic as normal or cancerous tissue. Only
tumor samples with the presence of at least 60% of tumor
cells were included. DNA from fresh-frozen tissue samples
was extracted using the DNA Mini Qiasymphony kit (Qiagen,
Valencia, CA), while DNA from FFPE samples was extracted
using the QIAamp DNA Micro Kit (Qiagen, Valencia, CA) as
previously reported (22).
This study was approved by the Institutional Review Board at
Barretos Cancer Hospital (Project number 1402/2017).
16S rRNA Gene Sequencing
Fifty nanograms of genomic DNA from 15 paired fresh-
frozen tumor and normal adjacent samples were used
to generate libraries of the V4 region of the 16S rRNA
(515F 5′-GTGCCAGCMGCCGCGGTAA-3′, 806R 5′-
GGACTACHVGGGTWTCTAAT-3′) (23) using the Fusion
PCR primer technology for templated bead preparation.
Genomic DNA targets amplification was carried out according to
the manufacturer’s instructions using Platinum PCR SuperMix
High Fidelity polymerase (Invitrogen, Carlsbad, California)
and bar-coded primers (Invitrogen, Carlsbad, California) at
Frontiers in Oncology | www.frontiersin.org 2 August 2019 | Volume 9 | Article 813
de Carvalho et al. Microbiota Impact in Colorectal Cancer
an annealing temperature of 56◦C for 40 cycles. PCR products
were cleaned up with Agencourt AMPure XP Kit Purification
system (Beckman Coulter, Brea, USA), quantified by Qubit,
and multiplexed at equimolar concentrations of 40 pM.
Template preparation and loading into Ion 314 v2 Chips (Life
Technologies, Carlsbad, California) was conducted using the Ion
Chef System (Life Technologies, Carlsbad, California) workflow
and sequencing was performed in an Ion Personal Genome
Machine (PGM) System using the Ion PGM Hi-Q View Chef Kit
(Life Technologies, Carlsbad, California). Bioinformatics analysis
of 16S sequencing is described in Supplementary Methods. The
data that support the findings of this study are openly available
in BioProject under sequence accession number PRJNA543496.
Quantitative PCR (qPCR) for Fn
Genomic DNA obtained from 152 tumor and 57 normal adjacent
fresh-frozen tissue samples and from 139 FFPE tumor samples
were subjected to quantitative PCR using TaqMan primer-probe
sets (Applied Biosystems) for the 16S ribosomal RNA gene DNA
sequence of Fn (nusG), and for the reference gene, SLCO2A1 as
previously described (24).
The primer and probe sequences used were as follows: nusG
forward primer, 5′-CAACCATTACTTTAACTCTACCATG
TTCA-3′; nusG reverse primer, 5′-GTTGACTTTACAGAAGG
AGATTATGTAAAAATC-3′; nusG probe, 6FAM-GTTGACTT




Each reaction contained 100 ng of genomic DNA run in
duplicate in 20-µL reactions containing 1 × final concentration
TaqMan Environmental Master Mix 2.0 (Applied Biosystems),
900 nM primers and 500 nM probes for each target gene.
Amplification and detection were performed with the
QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher
Scientific) using the following reaction conditions: 10min at
95◦C and 45 cycles of 15 s at 95◦C and 1min at 60◦C. DNA from
F. nucleatum subsp. nucleatum Knorr (ATCC 2558) was kindly
provided by Prof. Mario Julio Avila Campos (USP, SP, Brazil) and
used as positive control for all nusG runs.
In colorectal carcinoma cases with detectable Fn, the cycle
threshold (Ct) values in the quantitative PCR for nusG were
normalized by SLCO2A1 and used to calculate 2−1Ct values that
were used to quantify the amount of Fn DNA in each sample as
a relative unitless value (where 1Ct = the average Ct value of
nusG—the average Ct value of SLCO2A1) as previously described
(25). These samples were classified according to the amount of
bacteria found as low or high (Fn-low, Fn-high), on the basis
of the median cut point amount of Fn DNA in all samples
with positive results (tumor or normal adjacent), according to
sample storagemethod (fresh-frozenmedian= 4.5× 10−6, FFPE
median= 6.0× 10−6), as previously described (26).
Statistical Analysis
Statistical analysis was performed using the software IBM SPSS
Statistics 21 for Windows. Categorical variables were compared
using Fisher’s exact test. For all analysis, we considered statistical
significance when p ≤ 0.05 (two-sided).
We conducted univariate logistic regression analyses to assess
associations of the amount of tissue Fn DNA as a three-category
variable (Fn-negative, Fn-low, Fn-high) with the following
variables, using the negative status as a reference: tumor location,
the extent of the tumor into the wall of the colon or rectum
(T), tumor differentiation, MSI status, and BRAF mutations.
The multivariable logistic regression model initially included age
(continuous), sex, tumor location (proximal colon vs. distal or
rectum), MSI (positive vs. negative), BRAF (mutant vs. wild
type), and MLH1, MSH2, MSH6, and PMS2 protein expression
(negative vs. positive). A backward stepwise elimination with a
threshold of p = 0.05 was used to select variables in the final
models. To assess independent associations of MSI and tumor
location (predictor variables) with the amount of tissue Fn DNA
(an ordinal outcome variable; negative vs. low vs. high), we
performed univariate ordinal logistic regression analysis.
To test for associations between the presence of Fn DNA with
overall mortality and cancer-specific mortality, we classified it
into two categories: cases with detectable Fn DNA (Fn positive)
and cases without detectable Fn DNA (Fn negative). Kaplan–
Meier curves were constructed and the log-rank test was used
to assess differences in mortality between the two categories.
The Cox proportional hazards regression model was used to
control for confounders. Multivariable models included age
(continuous), sex, tumor location (proximal colon vs. distal or
rectum), MSI (positive vs. negative), BRAF (mutant vs. wild
type), and MLH1, MSH2, MSH6, and PMS2 protein expression
(negative vs. positive). A backward stepwise elimination with
a threshold of p = 0.05 was used to select variables in the
final models.
RESULTS
Microbial Diversity in Tumor and Normal
Tissues
The microbiota profile of 15 paired tumor and normal adjacent
tissues from patients with colorectal carcinoma was evaluated by
next-generation sequencing of V4 variable region of 16S rRNA.
A total of 2,198,654 good quality reads with a mean length of 269
base pairs were generated. A total of 41,844 OTUS comprising
all 30 samples (based on ≥99% of identity) were generated with
the UPARSE algorithm. The community structure represented
by diversity or richness was evaluated (from 0 to 30,000 reads)
using classical ecological indexes of alpha-diversity (Observed
OTUS, Chao1, PD_whole_tree, and Shannon Index) and by
constructing a rarefaction curve until both curves tended to reach
a plateau. Only nine CRC and normal tissue pairs reached the
plateau at 30,000 reads (Supplementary Figures 1A,B) with an
average of 1,406 OTUS in the tumor and 1,412 OTUS in the
normal tissue. The bacterial community of nine paired tumor
and normal adjacent tissues from this cohort was characterized.
The clinical and molecular characteristics of this subset of CRC
patients is presented in Supplementary Table 1. These samples
were used for downstream analyses of the taxonomic profile
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and differential abundance. The results of alpha diversity metrics
(Observed OTUs, Chao1, and Shannon) after rarefaction with
30,000 reads/samples of depth are also shown in boxplots of
Supplementary Figure 1C. No significant difference in alpha
diversity between the groups tested at the highest rarefaction
depths (30,000 reads/samples) was observed (ANOVA and t-
test; p > 0.05), suggesting that tumor and normal tissue
collected from the same patients have similar diversity of
species and richness.
The Unifrac unweighted beta diversity analysis also
showed that the overall bacterial community structure
and phylogenetic diversity in tumor and normal samples
tested were similar, as distinct clusters could not be
observed for the two sample types. The same analysis
showed that the most abundant genus (Enterotype)
involved in clustering this samples in similar groups is
represented by Fusobacterium, Bacteroides, and Escherichia
(Supplementary Figure 2).
Taxonomic Profiling of Microbiota in Tumor
and Normal Tissues
The analysis of the taxonomic profile at the phylum level
in tumor (T) and normal adjacent (N) tissue identified
Actinobacteria, Bacteroidetes, Euryarchaeota, Firmicutes,
Fusobacteria, Lentisphaerae, Proteobacteria, Spirochaetes,
Tenericutes, and Verrucomicrobia as the most frequent
(Figures 1A,B). The evaluation on paired tumor and normal
tissue from the same patient revealed that 6/9 sample (CR10N:
2.4% vs. CRC10T: 11.2%, CR24N: 0.7% vs. CR24T: 9.4%,
CR61N: 19.3% vs. CR61T: 35.5%, CR88T: 0.2% vs. CR88N:
11.5%, CR142N:13.3% vs. CR142T: 30.7%) were enriched in
Fusobacteria in the CRC tissue and 5/9 sample (CR10N: 12.7%
vs. CRC10T: 19%, CR24N: 7.8% vs. CR24T: 28.6%, CR68N: 7.8%
vs. CR68T: 18.7%, CR121N: 6.4% vs. CR121T: 27.4%) had an
increase of Proteobacteria (Figure 1A). We also analyzed the
taxonomic profile of all samples grouped by sample type (tumor
vs. normal) (Figure 1B).
FIGURE 1 | Taxonomic profile of the microbiota at phylum (>0.1%) level identified in colorectal carcinoma and normal adjacent mucosa pairs of samples (A) and
grouped by sample type (tumor vs. normal) (B). Differential abundance between tumor and normal tissue in log fold change (LogFC), showing significantly increased
phylum (C) and genus (D) in colorectal carcinoma in comparison to normal tissue (p < 0.05). T, colorectal carcinoma; N, normal adjacent mucosa.
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FIGURE 2 | Relative amount of F. nucleatum in colorectal cancer patients: (A) Fifty seven normal adjacent fresh-frozen tissue samples and 152 colorectal fresh-frozen
carcinoma tissue samples. Dot plots represent samples and the dotted line represents the median cut point amount (median = 4.5 × 10−6) around which samples
were classified as having high (above median) or low (below median) amount of F. nucleatum. (B) Overrepresentation of F. nucleatum in colorectal carcinoma tissue
samples in comparison to normal adjacent tissue in 57 paired cases. Statistical analysis was performed using independent Mann–Whitney test (A) and paired
Wilcoxon signed rank test (B). FF, fresh–frozen; NA, normal adjacent.
At the family level, 30 abundant members were identified
in tumor and normal samples (Supplementary Figure 3). When
results from the samples evaluated were grouped into tumor
and normal adjacent, Fusobacteriaceae (N: 7.5% vs. T: 15.8%),
Enterobacteriaceae (N: 6.7% vs. T: 8.8%), and Streptococcaceae
(N: 1.8% vs. T: 4.0%), were more enriched in the tumor tissue.
Finally, at the genus level, the most abundant genera identified
in the tumor tissue are described in Supplementary Figure 4.
Fusobacterium (N: 2.9% vs. T: 7.9%), Streptococcus (N: 1.8% vs.
T: 4.0%), Parvimonas (N: 1.0% vs. T: 1.8%), Aeromonas (N: 0.0%
vs. T: 1.0%), Campylobacter (N: 0.0% vs. T: 0.8%), Cetobacterium
(N: 0.0% vs. T: 0.7%), and Clostridium (N: 0.0% vs. T: 0.5%) were
most overrepresented.
The fluctuation and density of population frequencies of
Fusobacterium in CRC tumor (and normal adjacent tissue) were
evaluated using the two-dimensional kernel density tool (2D-
kde). This evaluation was able to reveal a gradual increase
of abundance (log10 transformed relative abundance) of the
Fusobacterium population from normal to tumor tissue, with a
higher density peak of the Fusobacterium population in tumor
(Supplementary Figure 5).
Phylum and Genera Abundance in Tumor
and Normal Tissues
The analysis of the log2 fold-change values of the differential
abundance between tumor and normal tissue showed that
the most significantly enriched phylum in CRC samples
evaluated were Fusobacteria, Proteobacteria, and Actinobacteria
(Figure 1C). The log2 fold-change values distribution of
differential abundance between tumor and normal tissue
showed that the most enriched genera in CRC is constituted by
Cetobacterium, Odoribacter, Fusobacterium, Peptostreptococcus,
Campylobacter, Aeromonas, Clostridium, and Parvimonas
(Figure 1D); all these genera were identified with a p-value below
0.05, while the genera Pseudomonas, Ruminococcus, Prevotella,
Paraprevotella, Leptotrichia, Bacteroides, and Treponema were
found depleted in CRC (Supplementary Figure 6).
Fn in Tumor and Normal Tissues
Since Fusobacterium genus was overexpressed in tumor tissue, we
further evaluated the presence of a fragment of the 16S ribosomal
RNA gene from Fn in tumor and normal adjacent samples.
Firstly, we evaluated tumor tissue of 152 fresh-frozen CRC
cases, and in a subset of 57 cases, we also assessed normal
adjacent tissue. Fn DNA was detected in 35 (23.0%) of the 152
colorectal carcinoma samples and in 6 (10.5%) of the 57 normal
adjacent tissue samples evaluated (Figure 2A; independent two-
tailed Mann–Whitney test, p = 0.0370). In the 57 pairs of
colorectal carcinoma and normal adjacent tissues, the amount
of Fn DNA was significantly higher in colorectal carcinoma
tissue than in the normal adjacent tissue, except for one patient
with proximal colon, MSI-positive and BRAF mutated tumor, in
which the level of Fn DNA was 11.88-fold higher in the normal-
adjacent tissue (Figure 2B, paired two-tailed Wilcoxon signed
rank test, p= 0.0038).
In the same cases, we further evaluated Fn in FFPE tumor
tissue. In the 139 colorectal carcinoma samples available to be
tested, Fn DNA was detected in only 8 (5.8%) of cases. There was
an absence of correlation between Fn detection between results
obtained from fresh-frozen tissue and FFPE samples (Cohen’s
Kappa test= 0.167; Supplementary Table 2).
The 35 fresh-frozen and eight FFPE CRC cases with detectable
Fn DNA were classified using the median cut point amount
(fresh-frozen median= 4.5× 10−6, FFPE median= 6.0× 10−6)
into two groups according to the level of Fn DNA: high (above
median) or low (below median) (Supplementary Tables 3, 4).
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TABLE 1 | Clinical, pathological, and molecular features according to the amount of Fusobacterium nucleatum (Fn) in fresh-frozen colorectal carcinoma tissue.
Variables All cases, n (%) Amount of Fn in tumor tissue (n = 152)
Fn-neg, n (%), n = 117 Fn-low, n (%), n = 17 Fn-high, n (%), n = 18 p-value†
Mean age (years) ± SD 60.63 ± 13.7
Gender
Female 71 (46.7) 53 (45.3) 7 (41.2) 11 (61.1) 0.406
Male 81 (53.3) 64 (54.7) 10 (58.8) 7 (38.9)
Tumor location
Proximal colon 38 (25.0) 21 (17.9) 7 (41.2) 10 (55.6) 0.001
Distal colon or rectum 114 (75.0) 96 (82.1) 10 (58.8) 8 (44.4)
Tumor (T)
Tis/T1/T2 53 (34.9) 47 (40.2) 2 (11.8) 4 (22.2) 0.035
T3/T4 (a b) 99 (65.1) 70 (59.8) 15 (88.2) 14 (77.8)
Clinical stage
E0/I 44 (28.9) 39 (33.3) 2 (11.8) 2 (16.7) 0.089
EII/III 102 (67.1) 74 (63.2) 13 (76.5) 15 (83.3)
EIV 6 (3.9) 4 (3.4) 2 (11.8) 0 (0.0)
Tumor differentiation
Well to moderate 139 (92.7) 110 (94.0) 17 (100.0) 12 (75.0) 0.011
Poor 11 (7.3) 7 (6.0) 0 (0.0) 4 (25.0)
MSI status#
MSI-negative 131 (86.2) 110 (94.0) 11 (64.7) 10 (55.6) <0.0001
MSI-positive 21 (13.8) 7 (6.0) 6 (35.3) 8 (44.4)
BRAF mutation$
Mutant 11 (7.3) 3 (2.6) 3 (17.6) 5 (27.8) <0.0001
Wild type 140 (92.7) 113 (97.4) 13 (76.5) 14 (77.8)
MLH1 protein expression#
Positive 117 (87.3) 101 (95.3) 8 (61.5) 8 (53.3) <0.0001
Negative 17 (12.7) 5 (4.7) 5 (38.5) 7 (46.7)
MSH2 protein expression#
Positive 131 (97.8) 105 (99.1) 11 (84.6) 11 (84.6) 0.003
Negative 3 (2.2) 1 (0.9) 2 (15.4) 2 (15.4)
MSH6 protein expression#
Positive 133 (99.3) 105 (99.1) 13 (100.0) 15 (100.0) 0.875
Negative 1 (0.7) 1 (0.9) 0 (0.0) 0 (0.0)
PMS2 protein expression#
Positive 119 (88.8) 102 (96.2) 9 (69.2) 8 (53.3) <0.0001
Negative 15 (11.2) 4 (3.8) 4 (30.8) 7 (46.7)
Percentage indicates the proportion of cases with a specific clinical, pathological, or molecular variable according to the amount of F. nucleatum DNA in colorectal cancer tissue.
†
To
assess associations between the ordinal categories (negative, low, and high) of the amount of F. nucleatum DNA in colorectal cancer tissue and categorical variables, Fisher’s exact test
was performed. #Previously reported by Berardinelli et al. (21); $Unpublished data; MSI, microsatellite instability.
Association of Fn With
Clinical–Pathological and Molecular
Features and Patient Survival
Clinical, demographic, and molecular data of the 152 CRC
patients evaluated are presented in Table 1. The mean age at
diagnostics was 60.63 (±13.7) years and 53.3% of the patients
profiled in this cohort were male. Regarding the primary tumor
site, most of the tumors were in the distal colon (75.0%), were
classified according to tumor stage as T3/T4 (65.1%) and with
EII/EIII clinical stage (28.9% of E0/1; 67.1% of EII/EIII; and 3.9%
EIV), and were well to moderately differentiated histologically
(92.7%) (Table 1). Results of MSI status (21), BRAF mutation
(unpublished data), and expression of mismatch-repair proteins
MLH1, MSH2, MSH6, and PMS2 (21) were obtained from
other studies from our group and are also described in Table 1.
Most of the patients were MSI-negative (92.7%), with MLH1,
MSH2, MSH6, and PMS2 expression (87.3, 97.8, 99.3, and
88.8%, respectively).
The association between clinical, pathological, and molecular
characteristics and the levels of Fn DNA detected (high, low, or
negative) in fresh-frozen tissue are summarized in Table 1. For
FFPE, results are summarized in Supplementary Table 4.
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TABLE 2 | Univariate odds ratio (OR) models adjusted by logistic regression of the
impact of the amount of Fusobacterium nucleatum (Fn) in colorectal cancer tissue
and clinical, pathological, and molecular data.
Variables Univariable OR (95% CI) p-value
Proximal vs. distal colon
Fn-negative 1 (reference)
Fn-low 3.20 (1.27–9.38) 0.034
Fn-high 5.71 (2.01–16.2) 0.001
T3/T4 vs. Tis/T1/T2
Fn-negative 1 (reference)
Fn-low 5.04 (1.10–23.05) 0.037
Fn-high 2.35 (0.73–7.58) 0.153
Poor vs. well to moderate
Fn-negative 1 (reference)
Fn-low Not evaluated Not evaluated
Fn-high 5.24 (1.34–20.5) 0.017
MSI-positive vs. MSI-negative#
Fn-negative 1 (reference)
Fn-low 8.57 (2.45–30.05) 0.001
Fn-high 12.57 (3.77–41.88) < 0.0001
Mutated vs. wild type BRAF$
Fn-negative 1 (reference)
Fn-low 8.07 (1.48–43.92) 0.016
Fn-high 14.49 (3.10–67.72) 0.0001
Negative vs. positive MLH1#
Fn-negative 1 (reference)
Fn-low 12.63 (3.01–52.94) 0.001
Fn-high 17.68 (4.56–68.50) <0.0001
Negative vs. positive MSH2#
Fn-negative 1 (reference)
Fn-low 19.09 (1.60–227.86) 0.02
Fn-high Not evaluated Not evaluated
Negative vs. positive PMS2#
Fn-negative 1 (reference)
Fn-low 11.33 (2.41–53.10) 0.002
Fn-high 22.31 (5.37–92.65) <0.0001
MSI, microsatellite instability; CI, confidence interval; OR, odds ratio. #Previously reported
by Berardinelli et al. (21); $unpublished data.
The amount of Fn DNA in fresh-frozen CRC tissue was
associated with proximal tumor location (p = 0.001), higher
depth of invasion (p = 0.035), poorly differentiated tumors (p
= 0.011), MSI-positive (p < 0.0001), BRAF mutated tumors (p
< 0.0001), and with the loss of expression of mismatch-repair
proteins MLH1 (p < 0.0001), MSH2 (p = 0.003), and PMS2
(p < 0.0001).
Either low, high, or both categories of Fn DNA positivity
showed a significant impact on all clinical, pathological, and
molecular data tested, as measured by univariate odds ratio (OR)
models adjusted by logistic regression (Table 2). In multivariable
logistic regression analyses, the amount of tissue Fn DNA was
statistically associated with MSI status: Fn-low had an OR of
6.812 (95% CI, 1.544 to 30.051; p= 0.011) for MSI-positive, while
Fn-high had an OR of 7.206 (95% CI, 1.769–29.357; p = 0.006).
TABLE 3 | Ordinal logistic regression analysis to assess associations of tumor
stage and MSI status with the amount of Fusobacterium nucleatum DNA in
colorectal cancer tissue.
Variables Odds ratio (95% CI) p-value
Fn-negative vs. Fn-low vs. Fn-high
Tumor stage (T3/T4 vs. Tis/T1/T2) 2.81 (1.04–7.55) 0.028
MSI (MSI-positive vs. MSI-negative)# 8.64 (3.33–22.39) <0.0001
MSI, microsatellite instability; CI, confidence interval. #Previously reported by Berardinelli
et al. (21).
Proximal tumors were also significantly associated with MSI-
positive status, with an OR of 16.685 (95% CI, 4.779–58.250; p <
0.0001). For the other variables tested in the univariate analysis,
no statistically significant association was observed with tissue Fn
DNA in the multivariable analyses.
We also performed an OR model adjusted by ordinal logistic
regression analysis to assess the impact of MSI status, tumor
extension through the wall (T), tumor location, differentiation,
status of BRAF mutation, and MLH1, MSH2, and PMS2 protein
expression in the amount of tissue Fn DNA. Only T3/T4 tumor
stage (OR, 2.81; 95% CI, 1.04–7.55; p for trend 0.028) and
MSI-positive (OR, 8.64; 95% CI, 3.33–22.39; p < 0.0001) were
associated with the amount of tissue Fn DNA (Table 3).
Regarding patient outcome, the presence of Fn DNA in CRC
fresh-frozen tissue was associated with shorter cancer-specific
survival (69.9 vs. 82.2% at 5 years; log-rank p= 0.028; Figure 3A)
and overall survival (63.5% vs. 76.5% at 5 years; log-rank p =
0.037; Figure 3B). Multivariable hazard ratio for cancer-specific
mortality in Fn positive cases was 2.255 (95% CI, 1.071–4.747;
p = 0.032), and that for overall survival was 2.011 (95% CI,
1.028–3.937; p= 0.041).
In FFPE CRC tissue, the amount of Fn DNA was associated
with proximal tumor location (p = 0.009), MSI-positive (p <
0.0001), BRAF mutated tumors (p = 0.002), and the loss of
expression of mismatch-repair proteins MLH1 (p < 0.0001) and
PMS2 (p< 0.0001). No further analyses were performed for these
cases, as the number of positive cases was very low.
DISCUSSION
The human microbiome represents a complex ecosystem
consisting of a large number of microorganisms that interact with
the environment and host (27–30) with accumulating evidence
showing their potential role in the pathogenesis of various
neoplasms including CRC (14, 31–34).
This study firstly unveiled the richness and abundance
of the microbial community of colorectal tumor samples in
comparison to adjacent normal mucosa through 16S rRNA
gene sequencing in a small cohort of Brazilian patients. Beta
diversity analyses showed a similar structure of phylogenetic
diversity of the bacterial community in CRC when compared
to normal tissue from the same patient, and similar results
have already been described in other studies (35, 36). However,
it also indicated a fine-tuning transition of abundance of
specific genera between the healthy microbiome present in
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FIGURE 3 | Kaplan–Meier curves for colorectal cancer-specific and overall survival according to the detection of Fusobacterium nucleatum (Fn) DNA in colorectal
tissue. (A) Five-year cancer-specific survival was of 69.9% for Fn positive and 82.2% for Fn negative (log-rank p = 0.028). (B) Five-year overall survival was of 63.5%
for Fn positive and 76.5% for Fn negative (log-rank p = 0.037).
normal tissue to potential oncogenic associated bacteria in
CRC. Our study identified an increase of Fusobacteria and
Proteobacteria phyla in CRC samples, which has been previously
associated with dysbiosis, inflammation, and CRC (35). At
the family level, the Enterobacteriaceae, Fusobacteriaceae, and
Streptococcaceae families were distinctly enriched in CRC.
Furthermore, we identified a core of microbiome enriched
in CRC constituted by genus Cetobacterium, Odoribacter,
Fusobacterium, Peptostreptococcus, Campylobacter, Aeromonas,
Clostridium, and Parvimonas. Consistent with our findings,
several others studies have reported Fusobacterium enrichment
in human CRC tissue in comparison with adjacent normal tissue
(37, 38). The combined population frequencies of Fusobacterium
coupled to Kernel density analysis revealed a fluctuating variation
in abundance of this genus from normal to CRC represented by a
rise and peaks of abundance in CRC.
Therefore, despite the complex profile of changes in the
balance of the intestinal microbiota, different metagenomic
studies have shown an enrichment of the genus Fusobacterium,
and most frequently the species Fn in adenomas and colorectal
carcinomas in comparison with normal adjacent mucosa samples
(18, 24, 37). The potential use of these microbes as non-invasive
biomarkers for the detection of CRC has been explored (39,
40). Recently, Dai et al. conducted a comprehensive meta-
analysis of shotgun metagenomics on CRC (41). The authors
explored changes in gut microbiome that were universal across
populations, by combining metagenomic data from 526 samples
from Chinese, Austrian, American, German, and French cohorts,
and found seven bacteria, including Fn, that were enriched
in CRC across these populations. These bacteria were able
to accurately classify cases (AUC = 0.80) across the different
populations, demonstrating a potential of bacterial markers as
robust diagnostic markers across populations (41).
The role of Fn in colonic carcinogenesis has been frequently
implicated with progression of advanced colorectal carcinoma,
and for this reason, this species has been mostly investigated
as a prognostic factor. Previous studies have suggested that this
species promotes colon carcinogenesis through the inhibition of
proliferation and induction of apoptosis in T cells (18). Other
studies revealed that elevated levels of Fn in the colon tissue are
inversely correlated with the density of T CD3+ cells and strongly
associated with MSI and CPG methylator phenotype (42, 43).
Given these complex interactions between thesemicroorganisms,
immunity, genetic profile, and CRC, this study evaluated the
abundance of Fn in DNA samples from CRC tissue through
quantitative PCR, and the association and impact of this species
in patient clinical and molecular features.
A recent study conducted a systematic review of all original
scientific articles published between 2000 and 2017 investigating
Fusobacterium and its relationship with CRC. After reviewing the
90 articles retrieved, the prevalence of Fn DNA in CRC tissue
varied between 8.6 and 87.1%. The authors suggest that the wide
variability observed could be explained by heterogeneity in study
design, sampling, analysis methodology, population, geographic
location, or diet (44). A recent study using samples fromBrazilian
CRC patients detected FnDNA in 33/43 (76.7%) of CRC samples
and also a very high rate of detection of Fn DNA in their
paired normal adjacent mucosa (31/43; 72.1%) (45). However,
the association between the presence of this bacteria and clinical
information was not evaluated in the Brazilian population.
Our study found a prevalence of 23% of Fn DNA in
(35/152) fresh-frozen CRC samples and of 10.5% (6/57) in the
normal adjacent tissue samples. The presence of Fn in fresh-
frozen tumor was associated with key clinical and molecular
features of CRC: proximal tumor location, higher depth of
invasion, higher clinical stages, poorly differentiated tumors,
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MSI-positive status, BRAF mutated tumors, and the loss of
MMR proteins, here represented by the lack of IHC expression.
Besides, either low, high, or both categories of Fn DNA positivity
showed a significant impact on all clinical, pathological, and
molecular data tested, as measured by univariate odds ratio
(OR) models adjusted by logistic regression. In the multivariable
model, together with proximal tumors, Fn low or high was
associated with MSI-positive status. The presence of Fn was
also associated with a higher cancer-specific mortality and
lower overall survival. These results agree with findings from
previous studies conducted in other populations, suggesting a
role of Fn with a subtype of more aggressive CRC and a worse
prognosis (42, 43, 46–49).
A much lower rate of positivity for Fn DNA was observed
in FFPE samples (5.8%), with a low concordance with fresh-
frozen results. Mima et al. previously acknowledged the
limitations of using FFPE tissue to detect microorganisms,
since routine histopathology procedures such as tissue fixation,
paraffin embedding, and storage may influence qPCR assay
results (43). Adding to this, it is known that in formalin-
fixed tissue, cross-linking of histone-like proteins to DNA or
fragmentation/degradation of genomic DNA occurs over time,
further decreasing the sensitivity of identifying organisms (50);
however, FFPE samples may be the only type of sample available
for testing. For this reason, we tested for associations of the
presence of Fn DNA in FFPE CRC and clinical and molecular
data and found similar results as already reported in previous
studies using both fresh-frozen and FFPE (42, 43, 46–49).
Alongwith the literature, our data reinforce specific organisms
as components of a microbiome core present in CRC tissues.
We observed that Fn is also found enriched in cohorts of
patients from Brazil and that the presence of this bacteria is
very likely to contribute to tumor aggressiveness and to a poor
prognosis. A more in-depth study of the association between the
metabolism of Fusobacterium and CRC can reveal the biological
role and involved factors in tumor progression and may lead to
personalized treatments.
In conclusion, we believe that tumor classification based on
the gut microbiome might provide a promising approach to
improve prediction of patient outcome. Despite the average
sample size of this study, we were able to validate features of
the association between the detection of Fn DNA and CRC
carcinogenesis that are already consolidated in other populations.
The findings presented here need to be validated in larger
cohorts of Brazilian patients to assess if this species can be
used as a marker in the Brazilian population, allowing a better
management of patient prognostication.
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